加载中
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
前收盘价
US$0.132
+US$0.002 · +1.54%
盘前
US$0.133
+US$0.001 · +0.76%
10月8日 8:48 ET
盘中时间采用ET。市场数据可能有所延迟。
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
日内区间
当前US$0.132
52周区间
当前US$0.132
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
41
合理估值
情绪
59
多空交织
风险
63
高风险
动量
17
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
日内区间
当前US$0.132
52周区间
当前US$0.132
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 7500 USD | 68.6万 USD | 28.4万 USD | 11万 USD |
| 毛利 | — | 7500 USD | 68.6万 USD | 28.4万 USD | 11万 USD |
| 研究与开发 | 483.6万 USD | 472.34万 USD | 364.32万 USD | 609.79万 USD | 538.01万 USD |
| 销售、一般及管理费用 | 613.07万 USD | 626.93万 USD | 449.33万 USD | 363.97万 USD | 395.14万 USD |
| 营业费用 | 1096.67万 USD | 1099.26万 USD | 813.65万 USD | 973.76万 USD | 933.15万 USD |
| 利息收入 | 7.02万 USD | 12.26万 USD | 1577 USD | 4818 USD | 8759 USD |
| 利息支出 | 7587 USD | 1.22万 USD | 16.77万 USD | 25.19万 USD | 6.7万 USD |
| 折旧和摊销 | 45.31万 USD | 44.82万 USD | 42.55万 USD | 40.6万 USD | 8.48万 USD |
| 营业利润 | −1096.67万 USD | −1098.51万 USD | −745.05万 USD | −945.36万 USD | −922.15万 USD |
| 净利润 | −1095.54万 USD | −896.75万 USD | −1128.38万 USD | −1068.04万 USD | −893.97万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年8月21日 | 6.66:1 | — | — |
股票拆分 | 2024年7月1日 | 1:30 | — | — |
已生效 2025年8月21日
6.66:1
已生效 2024年7月1日
1:30
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
